Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer SK, Neurath M, Atreya R (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: S466-S467

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjz203.676

Authors with CRIS profile

Sarah Ellen Mesfin Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen Heike Knott Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Francesco Vitali Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Simon Hirschmann Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Timo Rath Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Frank Dörje Professur für Molekulare und Klinische Pharmazie Wolfgang Uter Professur für Epidemiologie Sarah Katharina Meyer Medizinische Fakultät Markus Neurath Lehrstuhl für Innere Medizin I (Medizin 1) Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Involved external institutions

Progenika Biopharma ES Spain (ES)

How to cite

APA:

Fischer, S., Mesfin, S.E., Klenske, E., Schmitt, H., Vitali, F., Hirschmann, S.,... Atreya, R. (2020). Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study. In JOURNAL OF CROHNS & COLITIS (pp. S466-S467). OXFORD: OXFORD UNIV PRESS.

MLA:

Fischer, Sören, et al. "Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2020. S466-S467.

BibTeX: Download